BCL2L1 and ischemia: Further, TAT systems have been used to deliver the anti-apoptotic protein Bcl-xL to brain in a transient focal ischemia/reperfusion model; attenuated injury was observed even with a 45-min interval between reperfusion onset and intraperitoneal administration of TAT-Bcl-xL [46].